J&J Slammed With $8B Verdict In Philly Risperdal Case

Law360 (October 8, 2019, 5:11 PM EDT) -- A Philadelphia jury hammered a Johnson & Johnson unit with an $8 billion punitive damages verdict on Tuesday after agreeing the company had recklessly ignored the risks that the antipsychotic drug Risperdal could lead to breast growth in adolescent boys as it pushed the medication for use in children.

The $8 billion punitive damages verdict Tuesday was the first allowed since Risperdal trials began in Philadelphia nearly five years ago. (Getty)

The jury sided with arguments that J&J subsidiary Janssen Pharmaceuticals Inc. had downplayed the risks of abnormal breast growth, a condition known as gynecomastia, associated with Risperdal and had pressed...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS